BLOG

Midtown biotech sells $75M to the public to show FDA the promise of psychedelics

Biotech company MindMed is shoring up its cash stockpile to inch its psychedelic therapies towards approval after the feds’ recent thumbs-down of using MDMA to treat post-traumatic stress disorder.